Negative enrichment of circulating tumor cells from unmanipulated whole blood with a 3D printed device
| Autor: | Mehmet Asim Bilen, Mert Boya, Bassel F. El-Rayes, A. Fatih Sarioglu, Mehmet Akce, Omer Kucuk, Chia-Heng Chu, Tevhide Ozkaya-Ahmadov, Ruxiu Liu, Brandi E. Swain |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male 3d printed Science Tumor cells Cell Count Pilot Projects Cell Separation Article Cancer screening Circulating tumor cell Antigen Prostate Cell Line Tumor Lab-On-A-Chip Devices Leukocytes Medicine Humans Whole blood Cancer Aged Multidisciplinary Lab-on-a-chip business.industry Microfluidic Analytical Techniques Middle Aged Neoplastic Cells Circulating Peripheral blood medicine.anatomical_structure Printing Three-Dimensional Cancer research Normal blood Female business |
| Zdroj: | Scientific Reports Scientific Reports, Vol 11, Iss 1, Pp 1-12 (2021) |
| ISSN: | 2045-2322 |
| Popis: | Reliable and routine isolation of circulating tumor cells (CTCs) from peripheral blood would allow effective monitoring of the disease and guide the development of personalized treatments. Negative enrichment of CTCs by depleting normal blood cells ensures against a biased selection of a subpopulation and allows the assay to be applied on different tumor types. Here, we report an additively manufactured microfluidic device that can negatively enrich viable CTCs from clinically-relevant volumes of unmanipulated whole blood samples. Our device depletes nucleated blood cells based on their surface antigens and the smaller anucleated cells based on their size. Enriched CTCs are made available off the device in suspension making our technique compatible with standard immunocytochemical, molecular and functional assays. Our device could achieve a ~ 2.34-log depletion by capturing > 99.5% of white blood cells from 10 mL of whole blood while recovering > 90% of spiked tumor cells. Furthermore, we demonstrated the capability of the device to isolate CTCs from blood samples collected from patients (n = 15) with prostate and pancreatic cancers in a pilot study. A universal CTC assay that can differentiate tumor cells from normal blood cells with the specificity of clinically established membrane antigens yet require no label has the potential to enable routine blood-based tumor biopsies at the point-of-care. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink